Natera, Inc. $NTRA Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 77.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 884 shares of the medical research company’s stock after selling 3,072 shares during the period. Farther Finance Advisors LLC’s holdings in Natera were worth $142,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC grew its holdings in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC lifted its position in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after buying an additional 1,847 shares during the last quarter. UniSuper Management Pty Ltd purchased a new position in Natera during the first quarter worth about $368,000. Arete Wealth Advisors LLC increased its position in shares of Natera by 7.5% during the first quarter. Arete Wealth Advisors LLC now owns 2,130 shares of the medical research company’s stock valued at $301,000 after acquiring an additional 148 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of Natera in the 1st quarter valued at approximately $244,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 3,848 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $229.08, for a total transaction of $881,499.84. Following the completion of the transaction, the chief executive officer directly owned 136,568 shares of the company’s stock, valued at approximately $31,284,997.44. This represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Herm Rosenman sold 48,419 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $227.42, for a total value of $11,011,448.98. Following the sale, the director directly owned 20,342 shares in the company, valued at $4,626,177.64. This trade represents a 70.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 343,280 shares of company stock worth $73,566,011 over the last three months. Company insiders own 5.63% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on NTRA. Citigroup began coverage on shares of Natera in a research report on Wednesday. They set a “buy” rating and a $300.00 price objective for the company. JPMorgan Chase & Co. raised their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Evercore ISI lifted their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Wells Fargo & Company boosted their price objective on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Sixteen investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $238.89.

Natera Stock Up 2.3%

NASDAQ NTRA opened at $254.40 on Thursday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a market capitalization of $35.19 billion, a PE ratio of -111.09 and a beta of 1.62. The firm has a 50 day moving average of $225.41 and a two-hundred day moving average of $185.27.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.26) earnings per share. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating and raised its price target to $270 (from $230), signalling stronger analyst conviction and a higher valuation anchor for NTRA. Guggenheim Sticks to Their Buy Rating for Natera (NTRA)
• Positive Sentiment: Natera entered a collaboration with Exelixis on the STELLAR-316 Phase 3 trial of zanzalintinib for colorectal cancer — a potential revenue and pipeline catalyst for Natera’s oncology offerings (Signatera MRD monitoring could benefit). Exelixis and Natera to Collaborate on STELLAR-316
• Positive Sentiment: Coverage of the Exelixis collaboration in other outlets is driving momentum for both stocks, highlighting clinical validation and near-term trial milestones that could lift demand for Natera’s oncology assays. Exelixis and Natera stocks rise on colorectal cancer trial collaboration
• Positive Sentiment: Natera launched a 21‑gene Fetal Focus™ single‑gene NIPT powered by its LinkedSNP™ technology, expanding reproductive‑health product breadth and potential revenue per test. Product launches can improve near‑term commercial outlook if adoption accelerates. Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT
• Neutral Sentiment: Broad market coverage and price tracking pieces summarize the stock’s move and analyst consensus; useful context but not direct catalysts. Natera (NTRA) share price
• Negative Sentiment: Significant insider selling has been reported: multiple executives and insiders (including CEO Steven Chapman and Solomon Moshkevich) recently sold shares; a report aggregates ~US$47M in insider sales—this can create investor caution or signal profit‑taking. Insiders At Natera Sold US$47m In Stock
• Negative Sentiment: SEC Form 4 filings show recent CEO and other insider sales (details & timing), which may weigh on sentiment until management commentary clarifies intent. SEC filing – CEO sale

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.